Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
46 hedge funds and large institutions have $27.9M invested in Lumos Pharma, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 19 reducing their positions, and 29 closing their positions.
9% less capital invested
Capital invested by funds: $30.5M → $27.9M (-$2.6M)
28% less funds holding
Funds holding: 64 → 46 (-18)
53% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 19
55% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 29
72% less call options, than puts
Call options by funds: $467K | Put options by funds: $1.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$13.1M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$7.36M |
| 3 |
Blackstone Inc
New York
|
+$6.54M |
| 4 |
JG
Jefferies Group
New York
|
+$1.49M |
| 5 |
LPC
Lion Point Capital
New York
|
+$854K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.3M |
| 2 |
Two Sigma Investments
New York
|
-$849K |
| 3 |
QI
QS Investors
New York
|
-$270K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$265K |
| 5 |
RCM
Requisite Capital Management
Dallas,
Texas
|
-$253K |
LUMO Hedge Fund Activity: Q1 2020 in Review
46 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2020, worth a combined $27.9M — down 8.5% from $30.5M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of LUMO and 13 opened new positions — a net loss of 16 holders — while 19 trimmed existing stakes and 9 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $13.1M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $1.3M sold.
- 46 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2020, down from 64 in Q4 2019.
- Funds reported $27.9M of Lumos Pharma, Inc. Common Stock stock for Q1 2020, down 8.5% quarter-over-quarter.
- 13 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2020 and 29 closed out, a net change of -16 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2020 was Deerfield Management, an estimated $13.1M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q1 2020 was Acadian Asset Management, an estimated $1.3M sold.
Based on aggregated 13F filings for Q1 2020.